Abstract
Atrial fibrillation (AF) pharmacological and ablation studies are routinely performed in large animal models. There is growing interest from the FDA (cipa.org) and European Medicines Agency (EMA) in the development and application of simulations to augment animal pre-clinical studies, which has the potential to reduce the use of animal experiments. We propose developing a virtual human atria cohort from extensive patient data. We will confirm that the virtual cohort can act as a ground truth for signal processing algorithms, can be used for testing innovative ablation strategies and can be used to identify potential drug targets for pharmacologically treating AF.
References
https://pubmed.ncbi.nlm.nih.gov/33041850/
https://pubmed.ncbi.nlm.nih.gov/33716795/
https://pubmed.ncbi.nlm.nih.gov/33610744/
https://pubmed.ncbi.nlm.nih.gov/32782641/
https://pubmed.ncbi.nlm.nih.gov/30476055/